Original articleDiagnosis and Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis with Ocular Complications
Section snippets
Patients and Methods
From November 2005 through May 2008, extensive interviews were conducted with 94 patients (45 males and 49 females) with SJS or TEN with ocular complications seen at the SJS outpatient service at Kyoto Prefectural University Hospital. Of those patients, 88 cases were referral patients from the greater Japan area who had come to the SJS service at the acute stage (n = 14) or at the chronic stage (n = 74). Their ages ranged from 1 to 83 years (mean age±standard deviation, 41.6±18.5 years). At
Results
Of the 94 patients, drugs were the most commonly associated etiologic factor in 84 patients (89.4%). The causative drugs were cold remedies in 30 patients, antibiotics in 23 patients, nonsteroidal anti-inflammatory drugs in 19 patients, anticonvulsants in 5 patients, and others (anticancer agents, antirheumatic drugs, antimalarial, Chinese medicine, etc.).
Best-corrected visual acuity obtained at the chronic stage was 20/20 or better in 34 eyes (18.3%; Fig 1A), worse than 20/20 and up to and
Discussion
Stevens-Johnson syndrome and TEN are rare but potentially fatal skin disorders. Ocular involvement is common and often results in long-term complications such as serious visual impairment with ocular discomforts.13, 28 Although much has been learned over the past 50 years about the management of SJS and TEN, the following 3 important problems still remain: (1) the difficulty of obtaining a prompt and accurate diagnosis of SJS or TEN at disease onset, (2) ocular involvement often is overlooked
References (41)
- et al.
Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006
Allergol Int
(2007) - et al.
Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs: the EuroSCAR-study
J Invest Dermatol
(2008) - et al.
Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum
Ophthalmology
(1995) - et al.
Penetrating keratoplasty in cicatrizing conjunctival diseases
Ophthalmology
(1995) - et al.
New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome
Ophthalmology
(2007) - et al.
Existence of slow-cycling limbal epithelial basal cells that can be preferentially stimulated to proliferate: implications on epithelial stem cells
Cell
(1989) - et al.
Characteristics of the human ocular surface epithelium
Prog Retin Eye Res
(2001) - et al.
Limbal stem cell transplantation in chronic inflammatory eye disease
Ophthalmology
(2002) - et al.
Cultivated corneal epithelial stem cell transplantation in ocular surface disorders
Ophthalmology
(2001) - et al.
A comparison between cultivated and conventional limbal stem cell transplantation for Stevens-Johnson syndrome
Am J Ophthalmol
(2007)
Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study
J Am Acad Dermatol
Strong association between HLA-A*0206 and Stevens-Johnson syndrome in the Japanese
Am J Ophthalmol
Association of IL4R polymorphisms with Stevens-Johnson syndrome [letter]
J Allergy Clin Immunol
A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children
Am J Dis Child
Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme
Arch Dermatol
Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme
J Dermatol
Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study
Arch Dermatol
Severe adverse cutaneous reactions to drugs
N Engl J Med
Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis
N Engl J Med
Differential diagnosis of severe cutaneous drug eruptions
Am J Clin Dermatol
Cited by (137)
Diagnosis and Management of Immune-mediated Disorders of the External Eye
2024, Advances in Ophthalmology and OptometryTopical Betamethasone Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis with Ocular Involvement in the Acute Phase
2023, American Journal of OphthalmologyVulvovaginal and ocular involvement and treatment in female patients with Stevens–Johnson syndrome and toxic epidermal necrolysis: A review
2021, International Journal of Women's DermatologyCitation Excerpt :Medical treatment of acute ocular involvement in SJS /TEN is directed toward aggressively reducing inflammation with systemic immunosuppression and/or topical steroid therapy depending on the severity of the disease. Sotozono et al. (2009) reported that early topical steroid use resulted in significantly better visual outcomes in a study of 94 patients with SJS. Additionally, aggressive hourly topical lubrication with preservative-free artificial tears is necessary to dilute the concentrations of proinflammatory agents and support epithelial healing (Jain et al., 2016).
Corticosteroid Pulse Therapy for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Patients With Acute Ocular Involvement
2021, American Journal of Ophthalmology
Manuscript no. 2008-1063.
Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Supported in part by Health and Labor Sciences Research Grants (Research on Intractable Diseases) from the Ministry of Health, Labour and Welfare of Japan, Tokyo, Japan; the Japanese Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan; the Kyoto Foundation for the Promotion of Medical Science, Kyoto, Japan; and the Intramural Research Fund of Kyoto Prefectural University of Medicine, Kyoto, Japan.